The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Indianapolis-based pharmaceutical giant Eli Lilly and Co. announced plans Wednesday to add four new manufacturing sites in a ...

The move comes after President Donald Trump warned Big Pharma leaders that he would impose tariffs on them if they refuse to ...

The pharmaceutical company expects the expansion will create thousands of jobs.

GLP-1 Receptor Agonist Market. The global GLP-1 receptor agonist market is on the verge of unprecedented growth, fueled by ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly fivefold to $35.8 ...

Eli Lilly and Company said Wednesday they plan to build new pharmaceutical manufacturing sites in the United States.

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...